Atezolizumab After Adoptive Cell Transfer for Cancer
Trial Summary
What is the purpose of this trial?
This pilot phase I trial studies the side effects of atezolizumab in treating patients with cancer following adoptive cell transfer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Will I have to stop taking my current medications?
The trial requires that you stop any anti-cancer therapy, including adoptive cell transfer, for 28 days before starting atezolizumab. Additionally, you must not take systemic immunosuppressive medications within 2 weeks before starting the trial. Other medications, like hormone-replacement therapy or oral contraceptives, are allowed.
What data supports the effectiveness of the drug Atezolizumab (Tecentriq) for cancer treatment?
Atezolizumab has shown promising results in treating various cancers, including bladder cancer, where it improved response rates and survival compared to other treatments. It has also been effective in non-small cell lung cancer and triple-negative breast cancer, leading to its approval for these conditions.12345
Is atezolizumab generally safe for humans?
Atezolizumab, also known as Tecentriq, has been approved for use in several cancers and is generally considered to have an acceptable safety profile. Common side effects include fatigue, decreased appetite, and nausea, while more serious but less common effects can include lung inflammation, liver inflammation, and thyroid issues.46789
How is the drug atezolizumab unique in cancer treatment?
Atezolizumab is unique because it is a monoclonal antibody that targets PD-L1, a protein that helps cancer cells evade the immune system. By blocking this protein, atezolizumab enhances the body's immune response against tumors, making it different from traditional chemotherapy that directly targets cancer cells.124510
Research Team
Marcus Butler
Principal Investigator
University Health Network Princess Margaret Cancer Center LAO
Eligibility Criteria
Adults with advanced cancers not responding to standard treatments, who've had adoptive cell transfer (ACT), can join. They need a life expectancy over 3 months, certain blood and organ function levels, no recent cancer therapies except ACT, and measurable disease. Pregnant women or those with severe allergies to antibodies, active infections, or autoimmune diseases that could worsen are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive atezolizumab intravenously over 30-60 minutes on day 1, with cycles repeating every 21 days for a total of 17 doses over up to 12 months
Follow-up
Participants are monitored for safety and effectiveness after treatment completion, with follow-up at 4 weeks, 8 weeks, and then every 3 months
Treatment Details
Interventions
- Atezolizumab
Atezolizumab is already approved in United States, European Union for the following indications:
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor